Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

Activation of TRPV4 promotes osteoclasts differentiation

Author: Ritsuko Masuyama

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Osteoclast differentiation is critically dependent on cellular calcium (Ca2+) signaling. Intracellular Ca2+ concentration ([Ca2+]i) is regulated by two flux pathways; Ca2+ oscillations evoked by the release of Ca2+ from the endoplasmic reticulum, and/or Ca2+ entry from the extracellular fluid. The latter is carried out by the plasmamembrane localized Ca2+ permeable channel such as "transient receptor potentials (Trps)". Trpv4-deficient mice show an increased bone mass due to impaired osteoclast maturation, because Trpv4 mediates Ca2+ influx at the late stage of osteoclast differentiation and hereby regulates Ca2+ signaling [1]. Furthermore, substitutions of amino acids R616Q/V620I of Trpv4 have been discovered as gain of function mutations resulting in increased Ca2+ transport [2]. Since the region of these substitutions at the trans-membrane pore domain is perfectly conserved between species, we created a mutant of the mouse Trpv4 (Trpv4R616Q/V620I) and characterized it on Ca2+ signaling especially in the occurrences of oscillations at the initial step of osteoclast differentiation. …
Literature
1.
go back to reference Masuyama R, Vriens J, Voets T, Karashima Y, Owsianik G, Vennekens R, Lieben L, Torrekens S, Moermans K, Vanden Bosch A, et al: TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab. 2008, 8: 257-265. 10.1016/j.cmet.2008.08.002.CrossRefPubMed Masuyama R, Vriens J, Voets T, Karashima Y, Owsianik G, Vennekens R, Lieben L, Torrekens S, Moermans K, Vanden Bosch A, et al: TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab. 2008, 8: 257-265. 10.1016/j.cmet.2008.08.002.CrossRefPubMed
2.
go back to reference Rock MJ, Prenen J, Funari VA, Funari TL, Merriman B, Nelson SF, Lachman RS, Wilcox WR, Reyno S, Quadrelli R, et al: Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. Nat Genet. 2008, 40: 999-1003. 10.1038/ng.166.PubMedCentralCrossRefPubMed Rock MJ, Prenen J, Funari VA, Funari TL, Merriman B, Nelson SF, Lachman RS, Wilcox WR, Reyno S, Quadrelli R, et al: Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. Nat Genet. 2008, 40: 999-1003. 10.1038/ng.166.PubMedCentralCrossRefPubMed
Metadata
Title
Activation of TRPV4 promotes osteoclasts differentiation
Author
Ritsuko Masuyama
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3643

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine